Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms

키워드

참고문헌 (52)

1. Nangalia J, "Myeloproliferative neoplasms : from origins to outcomes", Blood, 130, pp.2475~2483 (2017)
2. Hasselbalch HC, "Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms : minimal residual disease and cure?", Semin Immunopathol, 41, pp.5~19 (2019)
3. Jia R, "Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions", Int J Hematol, 111, pp.182~191 (2020)
4. Ja Min Byun, "How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey", The Korean Journal of Internal Medicine, 37(2), pp.444~454 (2022), 대한내과학회[DOI]
5. Ik-Chan Song, "Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphianegative myeloproliferative neoplasm", The Korean Journal of Internal Medicine, 36(5), pp.1190~1203 (2021), 대한내과학회[DOI]
6. Bacigalupo A, "Allogeneic hemopoietic stem cell transplantation for myelofibrosis : 2021", Front Immunol, 12, pp.637512~ (2021)
7. Isaacs A, "Virus interference. I. The interferon", Proc R Soc Lond B Biol Sci, 147, pp.258~267 (1957)
8. Borden EC, "Interferons at age 50 : past, current and future impact on biomedicine", Nat Rev Drug Discov, 6, pp.975~990 (2007)
9. Kujawski LA, "The role of interferon-alpha in the treatment of chronic myeloid leukemia", Cytokine Growth Factor Rev, 18, pp.459~471 (2007)
10. 윤석윤, "The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms", Blood Research, 56, pp.44~50 (2021), 대한혈액학회[DOI]
11. Gisslinger H, "S196 : Ropeginterferon ALFA-2B achieves patient-specific treatment goals in polycythemia vera : final results from the Proud-PV", Continuation-PV studies, 2022, pp.6, 97~98
12. Abu-Zeinah G, "Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival", Leukemia, 35, pp.2592~2601 (2021)
13. Stein BL, "Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms", J Interferon Cytokine Res, 33, pp.145~153 (2013)
14. Chawla-Sarkar M, "Apoptosis and interferons : role of interferon-stimulated genes as mediators of apoptosis", Apoptosis, 8, pp.237~249 (2003)
15. Saleiro D, "Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms", Nat Commun, 13, pp.1750~ (2022)
16. Linkesch W, "Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses", Acta Med Austriaca, 12, pp.123~127 (1985)
17. Ludwig H, "Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders", Cancer Immunol Immunother, 25, pp.266~273 (1987)
18. Forsyth CJ, "Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms", Intern Med J, 49, pp.948~954 (2019)
19. Mascarenhas J, "A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia", Blood, 139, pp.2931~2941 (2022)
20. Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)
21. Kiladjian JJ, "High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a", Blood, 108, pp.2037~2040 (2006)
22. Kiladjian JJ, "Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b", Leukemia, 36, pp.1408~1411 (2022)
23. Yacoub A, "Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea", Blood, 134, pp.1498~1509 (2019)
24. Sørensen AL, "Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study", Haematologica, 105, pp.2262~2272 (2020)
25. Barbui T, "Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera(Low-PV study) : a multicentre, randomised phase 2 trial", Lancet Haematol, 8, pp.e175~e184 (2021)
26. Gisslinger H, "Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study", Lancet Haematol, 7, pp.e196~e208 (2020)
27. Ye J, "Interferon and hepatitis B : current and future perspectives", Front Immunol, 12, pp.733364~ (2021)
28. Verstovsek S, "SURPASS-ET : phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia", Future Oncol, 18, pp.2999~3009 (2022)
29. Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
30. Moliterno AR, "JAK2 V617F allele burden in polycythemia vera : burden of proof", Blood, 141, pp.1934~1942 (2023)
31. Vannucchi AM, "Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden", Leukemia, 21, pp.1952~1959 (2007)
32. Guglielmelli P, "JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis", Blood Cancer J, 11, pp.199~ (2021)
33. A-Jin Lee, "Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden", Blood Research, 56(4), pp.259~265 (2021), 대한혈액학회[DOI]
34. DePass LR, "Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains", J Toxicol Environ Health, 10, pp.297~305 (1982)
35. Adlard BP, "Maze learning by adult rats after inhibition of neuronal multiplication in utero", Pediatr Res, 9, pp.139~142 (1975)
36. Gangat N, "Myeloproliferative neoplasms and pregnancy : overview and practice recommendations", Am J Hematol, 96, pp.354~366 (2021)
37. Antonioli E, "Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN", Am J Hematol, 87, pp.552~554 (2012)
38. Alvarez-Larrán A, "Frequency and prognostic value of resistance", intolerance to hydroxycarbamide in 890 patients with polycythaemia vera, 2016, pp.172, 786~793
39. Alvarez-Larrán A, "Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera", Blood, 119, pp.1363~1369 (2012)
40. Verstovsek S, "Ruxolitinib versus best available therapy in patients with polycythemia vera : 80-week follow-up from the RESPONSE trial", Haematologica, 101, pp.821~829 (2016)
41. Sever M, "Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory", resistant to hydroxyurea, 2014, pp.55, 2685~2690
42. Alvarez-Larrán A, "Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea", Leukemia, 35, pp.623~627 (2021)
43. Bartels S, "Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2", Leukemia, 32, pp.556~558 (2018)
44. Cerquozzi S, "Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia : a literature review of incidence and risk factors", Blood Cancer J, 5, pp.e366~ (2015)
45. Qin A, "An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms : an overview of previous and ongoing studies with perspectives on the future", Front Oncol, 13, pp.1109866~ (2023)
46. Daltro De Oliveira R, "Interferon-alpha(IFN)therapy discontinuation is feasible in myeloproliferative neoplasm(MPN)patients with complete hematological remission", Blood, 136(Supplement 1), pp.35~36 (2020)
47. Utke Rank C, "Minimal residual disease after long-term interferon-alpha2 treatment : a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera", Leuk Lymphoma, 57, pp.348~354 (2016)
48. Tefferi A, "Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis", Blood, 124, pp.2507~2513 (2014)
49. Abu-Zeinah K, "Excess mortality in younger patients with myeloproliferative neoplasms", Leuk Lymphoma, 64, pp.725~729 (2023)
50. Goulart H, "Low-risk polycythemia vera and essential thrombocythemia : management considerations and future directions", Ann Hematol, 101, pp.935~951 (2022)
51. Yoon Seug Yun, "Novel therapeutic strategies for essential thrombocythemia", polycythemia vera, 2023, pp.58, 83~89[DOI]
52. Quintás-Cardama A, "Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a", Blood, 122, pp.893~901 (2013)

관련 논문AI추천